Last reviewed · How we verify
NCT04144595
Association Between Low Plasma Glucose After Oral Glucose Tolerance Test in Pregnancy With Impaired Fetal Growth
trial testing 2 hour 75 g Oral glucose tolerance test in Oral Glucose Tolerance Test in 300 participants. Completed in 30 November 2019.
28 October 2019
Quick facts
| Lead sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2019 |
| Primary completion | 28 October 2019 |
| Estimated completion | 30 November 2019 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- 2 hour 75 g Oral glucose tolerance test
Conditions studied
- Oral Glucose Tolerance Test — all drugs for Oral Glucose Tolerance Test →
- Low Birth Weight — all drugs for Low Birth Weight →
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Who can join
Eligibility, female only, with Oral Glucose Tolerance Test or Low Birth Weight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To study the association of low maternal plasma glucose in 2 hour 75 g oral glucose tolerance test (OGTT) in women with impaired birth weight and determinate if this result is predictive of low birth weight (\<10th percentile according to the INTERGROWTH-21st newborn weight standards for gestational age/sex). Materials and methods: OGTT at 24-34 week gestation will be performed in pregnant women, the birth weight will be compared between women with low fasting plasma glucose (FPG) (\<10th percentile, \<65 mg/dL) and normal FPG (≥10th percentile, ≥ 65 mg/dL) also for 1 and 2-hour plasma glucose (1-h PG/2-h PG). Receiver operating characteristic curve analysis will be used to determine the optimal lower OGTT threshold for the prediction of low birth weight.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prediction of low birth weight with hypoglycemia in glucose tolerance test.
Hernández-Castro F, Berlanga-Garza A, Cruz-Gutiérrez MD, Soria-López JA, et al · · 2021 · cited 2× · PMID 34008784 · DOI 10.11606/s1518-8787.2021055002543
Verify or expand the search:
- PubMed search for NCT04144595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hospital Universitario Dr. Jose E. Gonzalez trials
Trials by the same sponsor.
- NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
- NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting
- NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
- NCT07039877 — Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · Phase 2 · recruiting
- NCT06209190 — Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04144595 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Dr. Jose E. Gonzalez
- Last refreshed: 13 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing